A Randomized Controlled Trial of Darbepoetin Alfa Administered as a Fixed or Weight-Based Dose Using a Front-Loading Schedule in Patients with Anemia Who Have Nonmyeloid Malignancies

Cancer

Volumn 100, Issue 4, 2004, Pages 859-868

  Hesketh, Paul J ^a   Arena, Francis ^b   Patel, Dhimant ^c   Austin, Matt ^d   D'Avirro, Paul ^d   Rossi, Gregory ^d   Colowick, Alan ^d   Schwartzberg, Lee ^e  

^a ST ELIZABETH'S MEDICAL CENTER   (United States)

^b Arena Oncology Associates   (United States)

^c Rhinelander Medical Center   (United States)

^d AMGEN INC   (United States)

^e WEST CLINIC   (United States)

Author keywords

Anemia; Cancer; Dose administration; Erythropoietin

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BODY WEIGHT; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSE CALCULATION; DRUG DOSE REGIMEN; DRUG TOLERABILITY; DYSPNEA; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; FEVER; FRONT LOADING; HEMATOPOIESIS; HEMOGLOBIN DETERMINATION; HUMAN; KAPLAN MEIER METHOD; MAINTENANCE THERAPY; MALE; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOMITING;

AGED; ANEMIA; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; FEMALE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME;

EID: 0842304299     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11954     Document Type: Article

References (17)

1. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91:1616-1634.
2. Abels RI, Larholt KM, Krantz KD, Bryant EC. Recombinant human erythropoietin (rHuEPO) for the treatment of the anemia of cancer. In: Murphy MJ Jr., editor. Blood cell growth factors: their present and future use in hematology and oncology. Proceedings of the Beijing Symposium. Dayton: AlphaMed Press, 1991:121-142.
3. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol. 1998;16:3412-3425.
4. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo controlled, randomized Phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst. 2002;94:1211-1220.
5. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 1997;34(3 Suppl 2):13-19.
6. Elliot S, Lorenzini T, Asher S, et al. Enhancement of therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol. 2003;21:414-421.
7. Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999;10:2392-2395.
8. Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer. 2002;87:268-276.
9. Henry DH. Optimizing the treatment of anemia in cancer patients. Oncology. 2002;16:9-12.
10. Mirtsching B, Charu V, Vadhan-Raj S, et al. Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Oncology. 2002;16:31-36.
11. Kotasek D, Steger G, Faught W, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumors receiving chemotherapy: results of a double-blind, placebo-controlled, randomized study. Eur J Cancer. 2003;39:2026-2034.
12. Glaspy JA, Jadeja JS, Justice G, Fleishman A, Rossi G, Colowick AB. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin alfa for the treatment of anemia during cancer chemotherapy. Cancer. 2003;97:1312-1320.
13. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol. 2002;20: 4083-4107.
14. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol. 2001;19:2875-2882.
15. Jumbe NL, Rossi G, Heatherington AC. The science of erythropoiesis: quantification of factors influencing response by pharmacokinetic (PK) and pharmacodynamics (PD) modeling [abstract]. Blood. 2002;100:9b.
16. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. Epoetin Alfa Study Group. J Clin Oncol. 2001;19:2865-2874.
17. Amgen Inc. Aranesp® [package insert]. Thousand Oaks: Amgen Inc., 2002.